Gene Therapy in Oncology Market, by Type of Therapy (Gene-Based and Non-Gene-Based Therapy), by End User (Hospitals, Research Centers, Pharmaceutical Companies), by Indication (Solid Tumors, Hematological Cancers), by Delivery (Naked DNA Therapy, Vector Based Gene Therapy), by Product Type (Therapeutic Drugs, Gene Therapy Equipment) and, by Mode of Administration (Intravenous, Intramuscular, Intratumoral): Opportunity Analysis and Industry Forecast, 2023-2032

The report highlights the drivers, restraints, and opportunities of the market. It also provides the detailed information on the recent strategies incorporated by the key market players in the industry. It further emphasizes on how these strategies, which include partnership, expansion, collaboration, joint ventures, and others, are implemented to strengthen the market growth.

It is essential to understand the complete value chain to acquire a deep understanding of the market. To achieve this, AMR collects data from the top executives in the industry. Moreover, technical data is gathered from the intellectual property perspective, whereas technical trends are acquired from thorough assessments, technical symposia, and trade bulletins. This study presents an informative depiction of the global market along with the current trends and future estimations to support the investment pockets. Porter’s five forces analysis demonstrates the influence of buyers & suppliers in the market. The report provides a detailed market study based on economical intensity and how the global competition will take shape in the near future.

AMR is also involved in conducting in-depth product/service mapping. This, in turn, helps our experts comprehend the current trends and imminent technological benchmarking. Accordingly, the final material comprises an array of original data that is cross-checked and properly substantiated with published sources. Simultaneously, to reaccredit the leading key players and their respective market share, we organize paid telephonic interviews with industry doyens & whizzes to corroborate data collected from secondary sources and obtain relevant insights into the market.

Key Companies identified in the report are Brisol-Myers Squibb Co., Celgene Corporation, Novartis International AG, Astellas Pharma Inc., GlaxoSmithKline Plc., Pfizer Inc., Johnson and Johnson, Teva Pharmaceutical Industries Ltd., Astellas Pharma US Inc., AstraZeneca Plc.

The Report Features The Below Key Points

• The segment that generates the major share in terms of revenue

• The industry players and the strategies adopted by them

• Approaches taken by the players

• Detailed analysis of the value chain

  Gene Therapy in Oncology Market Report Highlights

Aspects	Details
By Type of Therapy	Gene-Based and Non-Gene-Based Therapy
By End User	Hospitals Research Centers Pharmaceutical Companies
By Indication	Solid Tumors Hematological Cancers
By Delivery	Naked DNA Therapy Vector Based Gene Therapy
By Product Type	Therapeutic Drugs Gene Therapy Equipment
By Mode of Administration	Intravenous Intramuscular Intratumoral
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Celgene Corporation, Astellas Pharma Inc., Astellas Pharma US Inc., Brisol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Novartis International AG, GlaxoSmithKline Plc., Johnson and Johnson, Pfizer Inc.

^*Terms and Conditions Apply